This webinar will share new evidence from Natera’s RenasightIQ™, linking genetic results with real-world outcomes across CKD in patients with:
Learn how clinicogenomic longitudinal data may impact the drug development lifecycle in nephrology.
Dr. Ronen Schneider is a clinician-scientist with expertise in the genetic mechanisms of nephrotic syndrome. He trained at Hadassah Hospital in Jerusalem, Israel, where he became an Attending Nephrologist before moving to the U.S. in 2016 for a postdoctoral research fellowship at Boston Children's Hospital (BCH). He most recently had dual roles as an Associate Physician in the Renal Division at Brigham and Women’s Hospital and a Principal Investigator at BCH. His research has focused on the molecular and clinical genetics of chronic kidney disease, leading to the discovery of novel monogenic causes of steroid-resistant nephrotic syndrome. He has co-authored over 40 peer-reviewed publications and led innovative work on gene therapy for glomerular diseases. Dr. Ronen has been actively involved in clinical nephrology, including co-directing the Renal Genetics and PKD Clinic at BWH. Currently, he is the Medical Director of renal genetics at Natera.
Dinah Clark has been a genetic counselor at Natera since 2011 and worked at The Children's Hospital of Philadelphia in the 10 years prior. Natera entered the organ health space in 2019, and since then, she has focused on renal genetics, managing clinical and scientific content that supports novel discoveries and pharma partnerships. Dinah graduated from Rutgers University with a BS in Biology and Psychology and received a Master's Degree in Genetic Counseling from Arcadia University.